ES2215048T3 - Derivados de furanona inhibidores de la catepsina s. - Google Patents

Derivados de furanona inhibidores de la catepsina s.

Info

Publication number
ES2215048T3
ES2215048T3 ES00929721T ES00929721T ES2215048T3 ES 2215048 T3 ES2215048 T3 ES 2215048T3 ES 00929721 T ES00929721 T ES 00929721T ES 00929721 T ES00929721 T ES 00929721T ES 2215048 T3 ES2215048 T3 ES 2215048T3
Authority
ES
Spain
Prior art keywords
alkyl
cycloalkyl
amino
rvii
riv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00929721T
Other languages
English (en)
Inventor
Martin Quibell
Steven Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir UK Ltd
Peptimmune Inc
Original Assignee
Medivir UK Ltd
Peptimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir UK Ltd, Peptimmune Inc filed Critical Medivir UK Ltd
Application granted granted Critical
Publication of ES2215048T3 publication Critical patent/ES2215048T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Compuesto según la fórmula (II): en la que: R1 = Ri, RiC(O), Ri C (S), Ri SO2u Ri OC(O), Ri NHC(O) Ri = X1 = O, S, NH; W, Y, Z = CH, N; Rii = combinaciones de sustitución individuales o múltiples en el anillo tomadas de: H, alquilo C1-7, alquilo C1-7 cicloalquilo C3-6, OH, SH, amino, halógeno; R2, R4 = H, alquilo C1-7, alquilo C1-7 cicloalquilo C3-7; R3 = alquilo C1-7, alquilo C1-7 cicloalquilo C3-7, alquilo Ar-C1-7; R5 =, alquilo C1-7, alquilo Ar-C1-7, alquilo C1u3- CONRiii, Riv, Riii = H, metilo; Riv = en las que n = 1 a 3, m = 1 a 3; Rv, Rvi = H, alquilo C1-7; A = N, CH; B = N, O, S, CH; Rvii = ausente cuando B = O, S; o Rvii = H, alquilo C1-7 cuando B = N, CH; Rviii = O, alquilo C1-7; R6 = H; y en las que, alquilo C1-7 o alquilo C1-3 pueden estar opcionalmente substituidos por uno o dos halógenos y/o un heteroátomo S, O, N, que si está localizado en un terminal de la cadena está substituido por uno o dos átomos de H; Ar es fenilo, pirazolilo, imidazolilo, oxazolilo, tiazinolilo, isotiazinolilo, oxadiazolilo, 1, 2, 3-triazolilo, furanilo o tienilo, que puede estar opcionalmente sustituido por alquilo halógeno C1-3, OH, alquilo OC1-3, SH, alquilo SC1- 3 o amino; amino es -NH2, alquil-NHC1-3 o - N(alquilo C1-3)2 y las sales farmacéuticamente aceptables de los mismos.
ES00929721T 1999-05-18 2000-05-18 Derivados de furanona inhibidores de la catepsina s. Expired - Lifetime ES2215048T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9911417.5A GB9911417D0 (en) 1999-05-18 1999-05-18 Furanone derivatives as inhibitors of cathepsin s
GB9911417 1999-05-18

Publications (1)

Publication Number Publication Date
ES2215048T3 true ES2215048T3 (es) 2004-10-01

Family

ID=10853598

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00929721T Expired - Lifetime ES2215048T3 (es) 1999-05-18 2000-05-18 Derivados de furanona inhibidores de la catepsina s.

Country Status (16)

Country Link
EP (2) EP1178986B1 (es)
JP (1) JP2002544274A (es)
AR (1) AR024040A1 (es)
AT (1) ATE260274T1 (es)
AU (1) AU763694B2 (es)
BR (1) BR0010553A (es)
CA (1) CA2374297A1 (es)
DE (1) DE60008524T2 (es)
DK (1) DK1178986T3 (es)
ES (1) ES2215048T3 (es)
GB (1) GB9911417D0 (es)
IL (2) IL146409A0 (es)
MX (1) MXPA01011872A (es)
MY (1) MY130768A (es)
PT (1) PT1178986E (es)
WO (1) WO2000069855A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171434A1 (en) * 2000-05-17 2003-09-11 Jackson Richard Francis William Branched amino acids
IL155958A0 (en) * 2000-11-17 2003-12-23 Medivir Ab Cysteine protease inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
MXPA03005601A (es) 2000-12-22 2004-12-02 Axys Pharm Inc Nuevos compuestos y composiciones como inhibidores de catepsina.
US7132449B2 (en) * 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
JP2004522738A (ja) * 2001-01-17 2004-07-29 アミュラ テラピューティクス リミテッド クルジパインおよび他のシステインプロテアーゼの阻害剤としての環状２−カルボニルアミノケトン
WO2002057270A1 (en) * 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
IL156776A0 (en) * 2001-01-17 2004-02-08 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
JP2005504078A (ja) 2001-09-14 2005-02-10 アベンティス・ファーマスーティカルズ・インコーポレイテツド カテプシン阻害剤としての新規化合物および組成物
CA2463770A1 (en) 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
MXPA04004450A (es) 2001-11-14 2004-08-11 Aventis Pharma Inc Nuevos compuestos y composiciones como inhibidores de catepsina s.
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
WO2004007501A1 (en) * 2002-07-16 2004-01-22 Amura Therapeutics Limited Biologically active compounds
EP1575576A2 (en) 2002-09-24 2005-09-21 Novartis AG Organic compounds
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
WO2005082876A1 (en) * 2004-03-01 2005-09-09 Medivir Uk Ltd C-5 substituted furanone dipeptide cathepsin s inhibitors
WO2006064286A1 (en) * 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
EP1916248A1 (en) * 2006-10-24 2008-04-30 Medivir Ab Furanone derivatives as cysteine protease inhibitors
WO2008104271A2 (en) 2007-02-28 2008-09-04 Sanofi-Aventis Imaging probes
EP2240491B1 (en) 2008-01-09 2015-07-15 Amura Therapeutics Limited TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
JP2011525189A (ja) 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
CA2251714A1 (en) * 1996-04-22 1997-10-30 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin s
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios

Also Published As

Publication number Publication date
IL146409A (en) 2005-11-20
CA2374297A1 (en) 2000-11-23
MY130768A (en) 2007-07-31
EP1413580A1 (en) 2004-04-28
AR024040A1 (es) 2002-09-04
ATE260274T1 (de) 2004-03-15
AU763694B2 (en) 2003-07-31
AU4772200A (en) 2000-12-05
DE60008524T2 (de) 2004-12-23
DE60008524D1 (de) 2004-04-01
IL146409A0 (en) 2002-07-25
GB9911417D0 (en) 1999-07-14
EP1178986B1 (en) 2004-02-25
EP1178986A2 (en) 2002-02-13
PT1178986E (pt) 2004-07-30
WO2000069855A3 (en) 2001-02-08
BR0010553A (pt) 2002-07-02
DK1178986T3 (da) 2004-07-05
WO2000069855A2 (en) 2000-11-23
MXPA01011872A (es) 2003-09-04
JP2002544274A (ja) 2002-12-24

Similar Documents

Publication Publication Date Title
ES2215048T3 (es) Derivados de furanona inhibidores de la catepsina s.
DK1323710T3 (da) Nitrogenholdige femleddede ringforbindelser
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
ES2304992T3 (es) Agentes antibacterianos de 3-aminoquinazolin-2,4-diona.
DK0457163T3 (da) Anvendelse af oxalyl-aminosyrederivater som lægemidler til inhibering af prolyl-hydroxylase
NO933964L (no) Nye perhydroisoindolderivater, deres fremstilling samt farmasoeytiske preparater inneholdende forbindelsene
ATE114670T1 (de) Phenylamidinderivate als plättchenaggregationsinhibitoren.
IL153594A0 (en) Amino alcohol derivatives and pharmaceutical compositions containing the same
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
WO2003037933A3 (de) Dermopharmazeutisch und kosmetisch wirksame oligopeptide
DE60236859D1 (de) Verbindung geeignet für den einsatz in organischen elektrolumineszenselementen und organische elektrolumineszenselemente
EA201170522A1 (ru) Новые гетероциклические азотсодержащие соединения, их получение и их применение в качестве антибактериальных лекарственных средств
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
BR0308492A (pt) Compostos cefem possuindo amplo espectro antibacteriano
AR035943A1 (es) Derivados de la quinolil propil piperidina, su preparacion y las composiciones farmaceuticas que los contienen
DE60202906D1 (de) Solubilisierung von 1,3,5-Triazinderivaten mittels Estern von N-Acylaminosäuren
EA200000400A1 (ru) Галогензамещенные тетрациклические производные тетрагидрофурана
GB2420781B (en) Aminopyrones and their use as ATM inhibitors
LV5794A4 (lv) Nonapeptidi ar bombezina antagonistu ipasibam
TW200635895A (en) PARP inhibitors
EA200701779A1 (ru) Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии
ES2180201T3 (es) Derivados de azetidinona para el tratamiento de infecciones por hcmv.
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
WO2006088720A3 (en) 9-substituted tetracyclines
ATE375350T1 (de) Modulatoren von peroxisome proliferator- aktivierten rezeptoren